MAIA Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 13
- Market Cap
- $66.9M
- Website
- http://maiabiotech.com
- Introduction
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3
Not yet recruiting
- Conditions
- Carcinoma, Non-Small -Cell Lung
- Interventions
- Drug: 6-Thio-2'-Deoxyguanosine
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Maia Biotechnology
- Target Recruit Count
- 300
- Registration Number
- NCT06908304
THIO Sequenced with Cemiplimab in Advanced NSCLC
Phase 2
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: 6-Thio-2'-Deoxyguanosine
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Maia Biotechnology
- Target Recruit Count
- 227
- Registration Number
- NCT05208944
- Locations
- 🇨🇳
Chang-Gung Memorial Hospital - Linko, Taoyuan City, Guishan District, Taiwan
🇹🇷Liv Hospital Ankara, Medikal Onkoloji Bilim Dalı, Ankara, Turkey
🇹🇷İstinye Üniversitesi Hastanesi Liv Hospital Bahçeşehir, Istanbul, Turkey
© Copyright 2025. All Rights Reserved by MedPath